Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Phasebio Pharmaceuticals Inc (PHAS)

Phasebio Pharmaceuticals Inc (PHAS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 124,508
  • Shares Outstanding, K 29,365
  • Annual Sales, $ 2,360 K
  • Annual Income, $ -39,250 K
  • 60-Month Beta 1.91
  • Price/Sales 50.87
  • Price/Cash Flow N/A
  • Price/Book 26.83
Trade PHAS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.76
  • Number of Estimates 3
  • High Estimate -0.71
  • Low Estimate -0.85
  • Prior Year -0.39
  • Growth Rate Est. (year over year) -94.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.07 +38.11%
on 11/05/20
4.25 -0.24%
on 12/04/20
+1.07 (+33.75%)
since 11/04/20
3-Month
2.60 +63.08%
on 10/28/20
4.25 -0.24%
on 12/04/20
+0.96 (+29.27%)
since 09/04/20
52-Week
2.60 +63.08%
on 10/28/20
8.49 -50.06%
on 01/10/20
+0.97 (+29.66%)
since 12/04/19

Most Recent Stories

More News
PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results

--Resuming enrollment in ongoing Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension

PHAS : 4.24 (+3.67%)
PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases,...

PHAS : 4.24 (+3.67%)
PhaseBio Provides Pemziviptadil (PB1046) Program Update

--Enrollment expected to resume for ongoing Phase 2b trial of pemziviptadil in pulmonary arterial hypertension (PAH)

PHAS : 4.24 (+3.67%)
PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor

--Bentracimab (PB2452) has demonstrated immediate and sustained reversal of the antiplatelet effects of ticagrelor in both Phase 1 and Phase 2 clinical trials

PHAS : 4.24 (+3.67%)
PhaseBio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases,...

PHAS : 4.24 (+3.67%)
PHASEBIO PHARMA (PHAS) Reports Q2 Loss, Lags Revenue Estimates

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -96.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PHAS : 4.24 (+3.67%)
PhaseBio Reports Recent Business Highlights and Second-Quarter 2020 Financial Results

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases,...

PHAS : 4.24 (+3.67%)
Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for

PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PHAS : 4.24 (+3.67%)
PhaseBio to Present at the William Blair Biotech Focus Conference 2020

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases,...

PHAS : 4.24 (+3.67%)
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More

The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.

IRWD : 11.98 (+3.45%)
REGN : 492.45 (-1.28%)
GILD : 61.56 (+1.15%)
ABIO : 4.19 (-1.64%)
NTLA : 43.44 (+1.21%)
PHAS : 4.24 (+3.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet...

See More

Key Turning Points

2nd Resistance Point 4.37
1st Resistance Point 4.31
Last Price 4.24
1st Support Level 4.12
2nd Support Level 3.99

See More

52-Week High 8.49
Fibonacci 61.8% 6.24
Fibonacci 50% 5.55
Fibonacci 38.2% 4.85
Last Price 4.24
52-Week Low 2.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar